abrdn Healthcare Investors (NYSE:HQH) Reaches New 1-Year High – Time to Buy?

Shares of abrdn Healthcare Investors (NYSE:HQH) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $19.79 and last traded at $19.51, with a volume of 1022 shares. The stock had previously closed at $19.33.

abrdn Healthcare Investors Price Performance

The company has a 50 day moving average of $19.10 and a 200 day moving average of $18.03.

abrdn Healthcare Investors Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, January 12th. Stockholders of record on Friday, November 21st were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 11.7%. The ex-dividend date was Friday, November 21st. This is an increase from abrdn Healthcare Investors’s previous quarterly dividend of $0.51.

Hedge Funds Weigh In On abrdn Healthcare Investors

A number of large investors have recently bought and sold shares of the stock. Eastern Bank purchased a new stake in shares of abrdn Healthcare Investors during the 3rd quarter valued at $30,000. Newbridge Financial Services Group Inc. acquired a new position in abrdn Healthcare Investors in the second quarter valued at $34,000. Guerra Advisors Inc purchased a new stake in abrdn Healthcare Investors during the third quarter valued at about $39,000. Geneos Wealth Management Inc. increased its stake in abrdn Healthcare Investors by 9,232.3% during the second quarter. Geneos Wealth Management Inc. now owns 2,893 shares of the financial services provider’s stock worth $45,000 after acquiring an additional 2,862 shares during the last quarter. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of abrdn Healthcare Investors in the 4th quarter worth about $48,000. Hedge funds and other institutional investors own 32.60% of the company’s stock.

abrdn Healthcare Investors Company Profile

abrdn Healthcare Investors (NYSE:HQH) is a closed-end management investment company that seeks long-term capital appreciation and current income by investing primarily in equity securities of companies operating in the healthcare sector. The fund’s portfolio generally comprises a diversified mix of domestic and international healthcare issuers, spanning pharmaceuticals, biotechnology, medical devices, healthcare services, and related industries.

The fund employs a fundamental, research-driven approach to select investments, focusing on companies with strong balance sheets, innovative product pipelines and the potential for sustainable revenue growth.